At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 772 enrolled
Drug / intervention
Secukinumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Multicenter Study to Assess the Efficacy and Safety of 16 Weeks Secukinumab Dosage Interval Shortening in Comparison to Continued Standard Treatment (4-weekly 300 mg s.c.) in Patients With Moderate-severe Plaque Type Psoriasis Who Achieved Less Than Almost Clear Skin After 16 Weeks Under the Standard Dose of Secukinumab
In Brief
A Phase 3 clinical trial evaluating Secukinumab for Moderate to Severe Plaque-type Psoriasis. Completed, enrolled 772 participants across 89 sites.
Detailed Summary
This study is designed to support the optimal use of secukinumab by providing data to refine guidance on dosing flexibility in patients with psoriasis. The purpose of the study is to explore the effects of dosage interval shorteng to achieve PASI 90 at week 32 for patients who had less than almost clear skin at week 16.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsModerate to Severe Plaque-type Psoriasis
CountriesGermany
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartFeb 2015
First PostedJun 2015
Primary CompletionSep 2016
TodayJul 2026
First PostedJun 17, 2015
Enrollment StartFeb 8, 2015
Primary CompletionSep 15, 2016
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 11.0 years ago
Interventions
Secukinumabdrug